EBOS Group Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume4,371 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield2.35%

Receive EBO News and Ratings via Email

Sign-up to receive the latest news and ratings for EBOS Group and its competitors with MarketBeat's FREE daily newsletter.

About EBOS Group

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand. It operates in two segments, Healthcare and Animal Care. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services. It also offers vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; community based health care services and programs; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that allows members drive their retail businesses. In addition, the company supplies health and wellness products public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers contract logistics services, such as healthcare distribution, warehousing, clinical trial management, and product registration services; and clinical trial logistics. Additionally, the company provides pet nutrition products, treats, clean-up products, grooming, and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was founded in 1922 and is headquartered in Docklands, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.24 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

EBOS Group (ASX:EBO) Frequently Asked Questions

What stocks does MarketBeat like better than EBOS Group?

Wall Street analysts have given EBOS Group a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but EBOS Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does EBOS Group pay dividends? What is the dividend yield for EBOS Group?

EBOS Group declared a Interim dividend on Wednesday, February 24th. Investors of record on Wednesday, March 17th will be given a dividend of 0.3512 per share on Wednesday, March 17th. This represents a yield of 1.33%. The ex-dividend date of this dividend is Wednesday, March 3rd.
View EBOS Group's dividend history

Is EBOS Group a good dividend stock?

EBOS Group pays an annual dividend of A$0.70 per share and currently has a dividend yield of 2.35%. The dividend payout ratio of EBOS Group is 65.48%. This payout ratio is at a healthy, sustainable level, below 75%.
View EBOS Group's dividend history.

Who are EBOS Group's key executives?

EBOS Group's management team includes the following people:
  • Mr. John Cullity, Chief Exec. Officer
  • Mr. Leonard Hansen, CFO & Chief Accountant
  • Ms. Andrea Bell, Chief Information Officer
  • Mark Connell, Mang. of Investor Relations
  • Ms. Janelle Cain, Gen. Counsel
  • Ms. Jacinta McCarthy, Group Gen. Mang. of Human Recourses
  • Mr. Brett Barons, Chief Exec. Officer of Symbion
  • Mr. Stuart Spencer, Exec. Gen. Mang. of Pharmacy & Institutional Healthcare

Who are some of EBOS Group's key competitors?

What other stocks do shareholders of EBOS Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EBOS Group investors own include (HEXO), FlexiGroup Limited (FXL.AX) (FXL), Fastly (FSLY) and De Grey Mining (DEG).

What is EBOS Group's stock symbol?

EBOS Group trades on the ASX under the ticker symbol "EBO."

How much money does EBOS Group make?

EBOS Group has a market capitalization of $0.00 and generates $9.04 billion in revenue each year.

How many employees does EBOS Group have?

EBOS Group employs 3,700 workers across the globe.

What is EBOS Group's official website?

The official website for EBOS Group is

How can I contact EBOS Group?

The company can be reached via phone at 61 3 9918 5555.

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.